133 related articles for article (PubMed ID: 18159211)
21. Introduction.
Reyes F
Semin Oncol; 2004 Feb; 31(1 Suppl 2):1. PubMed ID: 15042526
[No Abstract] [Full Text] [Related]
22. CD20-targeted therapy: a breakthrough in the treatment of non-Hodgkin's lymphoma.
van Meerten T; Hagenbeek A
Neth J Med; 2009; 67(7):251-9. PubMed ID: 19687518
[TBL] [Abstract][Full Text] [Related]
23. Using human CD20-transfected murine lymphomatous B cells to evaluate the efficacy of intravitreal and intracerebral rituximab injections in mice.
Mineo JF; Scheffer A; Karkoutly C; Nouvel L; Kerdraon O; Trauet J; Bordron A; Dessaint JP; Labalette M; Berthou C; Labalette P
Invest Ophthalmol Vis Sci; 2008 Nov; 49(11):4738-45. PubMed ID: 18552383
[TBL] [Abstract][Full Text] [Related]
24. Rituximab: gastrointestinal perforation.
Prescrire Int; 2007 Oct; 16(91):201. PubMed ID: 17929385
[No Abstract] [Full Text] [Related]
25. [Low-grade cutaneous B-cell lymphoma: Failure of intralesional rituximab (Mabthera)].
Abasq C; Duval-Modeste AB; Courville P; Joly P
Ann Dermatol Venereol; 2008; 135(6-7):509-11. PubMed ID: 18598807
[No Abstract] [Full Text] [Related]
26. Intravitreal methotrexate injections for intraocular involvement in primary central nervous system lymphoma.
Tourville E; Tardif Y
Can J Ophthalmol; 2003 Dec; 38(7):598-601. PubMed ID: 14740803
[No Abstract] [Full Text] [Related]
27. Sixth biannual report of the Cochrane Haematological Malignancies Group--focus on non-Hodgkin lymphoma.
Weingart O; Rehan FA; Schulz H; Naumann F; Knauel I; Bohlius CB; Engert A
J Natl Cancer Inst; 2007 Sep; 99(17):E1. PubMed ID: 17728205
[No Abstract] [Full Text] [Related]
28. Clinical investigations in aggressive non-Hodgkin lymphoma.
Jonathan F
Clin Adv Hematol Oncol; 2008 Sep; 6(9):7-8. PubMed ID: 18998259
[No Abstract] [Full Text] [Related]
29. Onset of psoriasis with psoriatic arthropathy during rituximab treatment of non-Hodgkin lymphoma.
Mielke F; Schneider-Obermeyer J; Dörner T
Ann Rheum Dis; 2008 Jul; 67(7):1056-7. PubMed ID: 18556453
[No Abstract] [Full Text] [Related]
30. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
31. GM1 expression of non-Hodgkin's lymphoma determines susceptibility to rituximab treatment.
Meyer zum Büschenfelde C; Feuerstacke Y; Götze KS; Scholze K; Peschel C
Cancer Res; 2008 Jul; 68(13):5414-22. PubMed ID: 18593944
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness of intrathecal rituximab in patients with acute lymphoblastic leukaemia relapsed to the CNS and resistant to conventional therapy.
Jaime-Pérez JC; Rodríguez-Romo LN; González-Llano O; Chapa-Rodríguez A; Gómez-Almaguer D
Br J Haematol; 2009 Mar; 144(5):794-5. PubMed ID: 19036096
[No Abstract] [Full Text] [Related]
33. FcgammaRIIa polymorphism and clinical response to rituximab in non-Hodgkin lymphoma patients.
Paiva M; Marques H; Martins A; Ferreira P; Catarino R; Medeiros R
Cancer Genet Cytogenet; 2008 May; 183(1):35-40. PubMed ID: 18474295
[TBL] [Abstract][Full Text] [Related]
34. A case of non-Hodgkin's lymphoma-associated pemphigus foliaceus and use of rituximab for treatment.
Prodanovic EM; Korman NJ
J Dermatolog Treat; 2008; 19(6):1-3. PubMed ID: 18720187
[TBL] [Abstract][Full Text] [Related]
35. [Chemotherapy in non-Hodgkin lymphoma].
Bremer K; Meusers P; Brittinger G
Internist (Berl); 1980 Sep; 21(9):512-28. PubMed ID: 7005175
[No Abstract] [Full Text] [Related]
36. Combined local chemotherapy for a spontaneously occurring intraocular tumour in a cat.
Rootman J; Bussanich N; Gudauskas G
Can J Ophthalmol; 1983 Jun; 18(4):185-7. PubMed ID: 6688371
[TBL] [Abstract][Full Text] [Related]
37. Classification updates and clinical investigations in indolent non-Hodgkin lymphoma.
Cheson BD
Clin Adv Hematol Oncol; 2008 Sep; 6(9):4-6. PubMed ID: 18998258
[No Abstract] [Full Text] [Related]
38. Optimizing the treatment of patients with rituximab-pretreated recurrent indolent non-Hodgkin lymphoma.
Leonard JP; Gregory SA; Maloney DG; Vose JM; Younes A; Zelenetz AD
Clin Adv Hematol Oncol; 2008 Jun; 6(6):437-45. PubMed ID: 18567989
[TBL] [Abstract][Full Text] [Related]
39. Rituximab in lymphoma with life threatening haemolysis.
Wong S; McKendrick J
Leuk Lymphoma; 2002 Aug; 43(8):1711-2. PubMed ID: 12400620
[No Abstract] [Full Text] [Related]
40. Rituximab in lymphocyte-predominant Hodgkin disease.
Azim HA; Pruneri G; Cocorocchio E; Cinieri S; Raviele PR; Bassi S; Preda L; Martinelli G; Peccatori FA
Oncology; 2009; 76(1):26-9. PubMed ID: 19033694
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
